Suppr超能文献

免疫疗法与放射疗法联合用于抗癌治疗的策略。

Strategies for combining immunotherapy with radiation for anticancer therapy.

作者信息

Seyedin Steven N, Schoenhals Jonathan E, Lee Dean A, Cortez Maria A, Wang Xiaohong, Niknam Sharareh, Tang Chad, Hong David S, Naing Aung, Sharma Padmanee, Allison James P, Chang Joe Y, Gomez Daniel R, Heymach John V, Komaki Ritsuko U, Cooper Laurence J, Welsh James W

机构信息

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, TX, USA.

出版信息

Immunotherapy. 2015;7(9):967-980. doi: 10.2217/imt.15.65. Epub 2015 Aug 27.

Abstract

Radiation therapy controls local disease but also prompts the release of tumor-associated antigens and stress-related danger signals that primes T cells to promote tumor regression at unirradiated sites known as the abscopal effect. This may be enhanced by blocking inhibitory immune signals that modulate immune activity through a variety of mechanisms. Indeed, abscopal responses have occurred in patients with lung cancer or melanoma when given anti-CTLA4 antibody and radiation. Other approaches involve expanding and reinfusing T or NK cells or engineered T cells to express receptors that target specific tumor peptides. These approaches may be useful for immunocompromised patients receiving radiation. Preclinical and clinical studies are testing both immune checkpoint-based strategies and adoptive immunotherapies with radiation.

摘要

放射治疗可控制局部疾病,但也会促使肿瘤相关抗原和应激相关危险信号的释放,这些信号会使T细胞致敏,从而促进未受照射部位的肿瘤消退,即所谓的远隔效应。通过阻断通过多种机制调节免疫活性的抑制性免疫信号,这一效应可能会增强。事实上,肺癌或黑色素瘤患者在接受抗CTLA4抗体和放射治疗时会出现远隔反应。其他方法包括扩增和回输T细胞或NK细胞,或改造T细胞以表达靶向特定肿瘤肽的受体。这些方法可能对接受放疗的免疫功能低下患者有用。临床前和临床研究正在测试基于免疫检查点的策略以及放疗联合过继性免疫疗法。

相似文献

1
Strategies for combining immunotherapy with radiation for anticancer therapy.
Immunotherapy. 2015;7(9):967-980. doi: 10.2217/imt.15.65. Epub 2015 Aug 27.
2
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419.
3
Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.
J Immunol Res. 2015;2015:675269. doi: 10.1155/2015/675269. Epub 2015 Oct 26.
4
Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Crit Rev Immunol. 2016;36(4):329-347. doi: 10.1615/CritRevImmunol.2017019376.
5
Challenges of cancer therapy with natural killer cells.
Cytotherapy. 2015 Mar;17(3):245-9. doi: 10.1016/j.jcyt.2014.09.007. Epub 2014 Dec 18.
6
Novel immunotherapies for hematologic malignancies.
Immunol Rev. 2015 Jan;263(1):90-105. doi: 10.1111/imr.12245.
7
Update on the current revolution in cancer immunotherapy.
Immunotherapy. 2019 Jan;11(1):15-20. doi: 10.2217/imt-2018-0135.
8
A new therapeutic potential for cancers: One CAR with 2 different engines!
Hum Vaccin Immunother. 2017 Aug 3;13(8):1786-1788. doi: 10.1080/21645515.2017.1314874. Epub 2017 May 11.
9
NK cell-based immunotherapy for cancer.
Semin Immunol. 2017 Jun;31:37-54. doi: 10.1016/j.smim.2017.07.009. Epub 2017 Aug 31.
10
[Immune-checkpoints: the new anti-cancer immunotherapies].
Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771.

引用本文的文献

2
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer.
Nat Rev Urol. 2024 Nov;21(11):676-686. doi: 10.1038/s41585-024-00913-8. Epub 2024 Aug 7.
4
A review on lymphocyte radiosensitivity and its impact on radiotherapy.
Front Oncol. 2023 Aug 3;13:1201500. doi: 10.3389/fonc.2023.1201500. eCollection 2023.
6
Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma.
Discov Oncol. 2023 Mar 16;14(1):32. doi: 10.1007/s12672-023-00638-x.
7
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
Clin Transl Radiat Oncol. 2023 Jan 20;39:100587. doi: 10.1016/j.ctro.2023.100587. eCollection 2023 Mar.
10
Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy.
Cancers (Basel). 2022 Feb 15;14(4):967. doi: 10.3390/cancers14040967.

本文引用的文献

1
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
2
Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells.
Cancer Med. 2015 Apr;4(4):551-64. doi: 10.1002/cam4.412. Epub 2015 Jan 30.
3
Designing chimeric antigen receptors to effectively and safely target tumors.
Curr Opin Immunol. 2015 Apr;33:9-15. doi: 10.1016/j.coi.2015.01.002. Epub 2015 Jan 23.
4
NK cells and T cells cooperate during the clinical course of colorectal cancer.
Oncoimmunology. 2014 Aug 3;3(8):e952197. doi: 10.4161/21624011.2014.952197. eCollection 2014.
6
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
7
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.
8
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验